Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

NCT03903640 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT03903640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03903640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Terminated
Start date
October 14, 2019
Completion date
November 3, 2021
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma with brain metastasis